• Revenue down 4.76% to $19.5 million
• NPAT down 399% to a loss of $5.7 million
• Significant strategic investments in B2C strategy and new product launches

ECS Botanics Holdings Ltd has reported its financial results for the year ended 30 June 2025. The company's revenue from ordinary activities declined 4.76% to $19.5 million, while profit (loss) from ordinary activities after tax attributable to members fell 399% to a loss of $5.7 million. The company made significant strategic investments during the year, including the introduction of its own-brand B2C strategy and the launch of two innovative product lines with strong intellectual property advantages. These initiatives have repositioned the company to deliver sustainable growth in FY2026, as demonstrated by leading indicators. The company's pivot to B2C has broadened its revenue base, strengthened its market position, and created a platform for ongoing growth. ECS has also continued to expand its sales and marketing capability, with strong momentum across both B2C and B2B channels. The company's team of experienced Medical Science Liaisons has been instrumental in driving prescriber engagement and patient uptake. Looking ahead, ECS expects its growth trajectory to accelerate in FY2026, driven by both organic growth and new product launches, including AVANI ADVANCED and the Terp Hogz premium genetics range. The company has also made strategic investments in its production facilities, including the addition of protective cropping enclosures and expanded processing and curing capacity, which are expected to be completed in October 2025.

ECS expects its growth trajectory to accelerate in FY2026, driven by both organic growth and new product launches, including AVANI ADVANCED and the Terp Hogz premium genetics range.

ECS has positioned itself to compete strongly and sustainably in the Australian market, with a clean balance sheet, a solid sales pipeline underpinned by high-quality products with compelling value propositions, and strong customer relationships. The company looks forward to a successful FY2026, which it expects to be a milestone year.